bupivacaine has been researched along with Spinal Diseases in 18 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Spinal Diseases: Diseases involving the SPINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 103 patients who were scheduled to undergo elective posterior lumbar discectomy, decompressive laminectomy with or without instrumented fusion for degenerative spinal diseases, received either methylprednisolone locally applied to the affected nerve roots (and bupivacaine was infiltrated into the wound) or injected placebo." | 5.12 | Peridural methylprednisolone and wound infiltration with bupivacaine for postoperative pain control after posterior lumbar spine surgery: a randomized double-blinded placebo-controlled trial. ( Jirarattanaphochai, K; Jung, S; Krisanaprakornkit, W; Sumananont, C; Thienthong, S, 2007) |
| " The rate of adverse events with conscious sedation has not been previously assessed in the interventional spine procedure setting." | 1.37 | Adverse events of conscious sedation in ambulatory spine procedures. ( Marín, DR; Schaufele, MK; Simmons, AC; Tate, JL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Katsevman, GA | 1 |
| Allison, AA | 1 |
| Fang, W | 1 |
| Confer, J | 1 |
| Elhamdani, S | 1 |
| Hoyt, A | 1 |
| Garavaglia, JM | 1 |
| Marsh, RA | 1 |
| O'Neill, KR | 1 |
| Lockney, DT | 1 |
| Bible, JE | 1 |
| Crosby, CG | 1 |
| Devin, CJ | 1 |
| Scuderi, GJ | 1 |
| Cuellar, JM | 1 |
| Cuellar, VG | 1 |
| Yeomans, DC | 1 |
| Carragee, EJ | 1 |
| Angst, MS | 1 |
| Schaufele, MK | 1 |
| Marín, DR | 1 |
| Tate, JL | 1 |
| Simmons, AC | 1 |
| Singh, K | 2 |
| Samartzis, D | 1 |
| Dip, DS | 1 |
| Strom, J | 1 |
| Manning, D | 1 |
| Campbell-Hupp, M | 1 |
| Wetzel, FT | 1 |
| Gupta, P | 1 |
| Phillips, FM | 2 |
| Meta, G | 1 |
| Ghaleb, A | 1 |
| Gentry, WB | 1 |
| Firnhaber, J | 1 |
| Kanniah, S | 1 |
| Amin, N | 1 |
| Brancaccio, R | 1 |
| Cohen, D | 1 |
| Jirarattanaphochai, K | 1 |
| Jung, S | 1 |
| Thienthong, S | 1 |
| Krisanaprakornkit, W | 1 |
| Sumananont, C | 1 |
| Kuo, E | 1 |
| Campbell, M | 1 |
| Schwarzer, AC | 2 |
| Wang, SC | 1 |
| Bogduk, N | 2 |
| McNaught, PJ | 1 |
| Laurent, R | 1 |
| Aprill, CN | 1 |
| Derby, R | 1 |
| Fortin, J | 1 |
| Kine, G | 1 |
| Crawford, RW | 1 |
| Gie, GA | 1 |
| Ling, RS | 1 |
| Murray, DW | 1 |
| Kim, KM | 1 |
| Kim, HS | 1 |
| Choi, KH | 1 |
| Ahn, WS | 1 |
| Goucke, CR | 1 |
| Graziotti, P | 1 |
| Wulf, H | 1 |
| Striepling, E | 1 |
| Moran, R | 1 |
| O'Connell, D | 1 |
| Walsh, MG | 1 |
| Reynolds, AF | 1 |
| Dautenhahn, DL | 1 |
| Pollay, M | 1 |
| Fagraeus, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Local Anesthetic Use at Iliac Crest Bone Graft Site in Spinal Reconstructive Surgery[NCT01087931] | 40 participants (Actual) | Interventional | 2010-04-30 | Completed | |||
| Using Inflammatory Biomarkers and EMG Results to Predict Epidural Injection Response in Patients Diagnosed With Lumbar Stenosis[NCT03511053] | 11 participants (Actual) | Interventional | 2017-12-19 | Completed | |||
| Role of Continuous Local Infusion of Ropivacaine for Post-Operative Pain Management in Patients Receiving Osseocutaneous Free Flaps[NCT03349034] | Phase 2 | 24 participants (Actual) | Interventional | 2017-09-13 | Completed | ||
| Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation[NCT01872494] | Phase 4 | 71 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy for Herniated Lumbar Discs Is There a Role? - A Randomized Control Trial[NCT04182997] | Phase 4 | 200 participants (Anticipated) | Interventional | 2019-11-21 | Recruiting | ||
| Perioperative IV Steroid Administration Lowers Post-operative Pain Levels and Opioid Use in Pediatric Patients After Posterior Spinal Fusion and Instrumentation for Spine Deformity.[NCT05287035] | Early Phase 1 | 70 participants (Anticipated) | Interventional | 2023-07-01 | Enrolling by invitation | ||
| Comparative Outcomes of Intraoperative Epidural Application of Anesthetic Cocktail Following Endoscopic Lumbar Discectomy: A Randomized Controlled Trial[NCT05738759] | 54 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| A Randomized Placebo-Controlled Trial of Platelet Rich Plasma (PRP) for Facet Mediated Lumbar Low Back Pain[NCT04822753] | 170 participants (Anticipated) | Interventional | 2021-09-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants using narcotics for pain (NCT01087931)
Timeframe: about 4 to 5 weeks after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupivacaine | 9 |
| Saline | 13 |
Number of participants using narcotics for pain (NCT01087931)
Timeframe: about 18 to 20 weeks after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupivacaine | 1 |
| Saline | 3 |
Cumulative Visual Analog Score pain score scores were calculated using the sum of scores (at rest and with movement, pain on average at rest and with movement, and maximum pain at rest and with movement) Range = 0-60 for cumulative visual analog pain score with 0=no pain and 60=worst pain ever. (NCT01087931)
Timeframe: about 4 to 5 weeks after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Bupivacaine | 10.5 |
| Saline | 21.7 |
Cumulative Visual Analog Score pain score scores were calculated using the sum of scores (at rest and with movement, pain on average at rest and with movement, and maximum pain at rest and with movement) Range = 0-60 for cumulative visual analog pain score with 0=no pain and 60=worst pain ever. (NCT01087931)
Timeframe: about 18 to 20 weeks after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Bupivacaine | 15.33 |
| Saline | 29.33 |
Measures how pain is affecting the patients lifestyle on a scale from 0 to 10 as defined by each question. The questionnaire contains 15 questions that each range on a scale form 0 to 10. The total score of the questionnaire ranges from 0 to 150. Lower values represent a better outcome. (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average at 1 month change | Average at 2 month change | |
| All Participants | 77.5 | 53.3 | 64.3 | 27.3 | 16.2 |
Measures how pain due to spinal stenosis is effected the patient based on quality of life/pain questions and satisfaction questions for months 1 and 2 (no scales are used) SSSQ scores are reported in percentages 0-100%, higher scores indicate worse outcomes. (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | Percentage (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average at 1 month change | Average at 2 month change | |
| All Participants | 64.1 | 53.2 | 53.5 | 11.7 | 10.3 |
Number rating of back/leg pain from 0 to 10, 0 being no pain/discomfort, 10 being extreme pain/discomfort (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average 1 month change | Average 2 month change | |
| All Participants | 6.2 | 5.0 | 5.0 | 0.8 | 1 |
Pain question on APS-POQ-R - A standardized pain satisfaction survey distributed to subjects at 48 hours rating their overall satisfaction with postoperative pain management. a 16-item questions measured on a 10-point numeric likert scale, with higher scores indicating more pain. Total range from 0 (no pain) to 200 (severe pain). (NCT03349034)
Timeframe: 48 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Saline Placebo | 6.0 |
| Ropivacaine | 4.3 |
At 48 hours all subjects received a physical therapy evaluation. Distance ambulated measured in feet. (NCT03349034)
Timeframe: 48 hours
| Intervention | feet (Mean) |
|---|---|
| Saline Placebo | 152 |
| Ropivacaine | 80 |
All subjects receive standing tylenol 650mg every 6 hours as well as a dilaudid PCA set for low-dose, opioid-naive patients for the first 48 hours post-operatively. Total opioid consumption for each subject during the first 48 hours is recorded measured in oral morphine equivalents (OME). (NCT03349034)
Timeframe: 48 hours
| Intervention | OME (Mean) |
|---|---|
| Saline Placebo | 119.75 |
| Ropivacaine | 91.20 |
At 48 hours all subjects received a physical therapy evaluation. Strength measured on a standard neurological 5 point scale: 0 = Complete Paralysis to 5 = Normal Power. (NCT03349034)
Timeframe: 48 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Saline Placebo | 2.67 |
| Ropivacaine | 2.20 |
"Pain assessed every 8 hours for the first 48 hours using a visual analogue pain scale at rest. A visual analogue pain scale is a validated pain measure. Essentially, there is a 100 millimeter line drawn on a piece of paper, with no pain marking the left end of the line and worst pain marking the right end of the line. Subjects mark with a pen along the line where pain is felt fits along that continuum. A researcher then measures how far along the line that mark is placed and then it is recorded. Full scale from 0-100, higher score indicates more pain." (NCT03349034)
Timeframe: 8, 16, 24, 32, 40 and 48 hours
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| 8 hour | 16 hour | 24 hour | 32 hour | 40 hour | 48 hour | |
| Ropivacaine | 40.14 | 26.56 | 41.56 | 35.67 | 33.60 | 37.40 |
| Saline Placebo | 44.00 | 27.50 | 31.83 | 24.17 | 21.88 | 20.38 |
"Pain assessed every 8 hours for the first 48 hours using a visual analogue pain scale at rest. A visual analogue pain scale is a validated pain measure. Essentially, there is a 100 millimeter line drawn on a piece of paper, with no pain marking the left end of the line and worst pain marking the right end of the line. Subjects mark with a pen along the line where pain is felt fits along that continuum. A researcher then measures how far along the line that mark is placed and then it is recorded. Full scale from 0-100, higher score indicates more pain." (NCT03349034)
Timeframe: 8, 16, 24, 32, 40 and 48 hours
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| 8 hour | 16 hour | 24 hour | 32 hour | 40 hour | 48 hour | |
| Ropivacaine | 41.14 | 40.88 | 45.67 | 37.44 | 42.11 | 30.60 |
| Saline Placebo | 52.40 | 41.00 | 23.33 | 25.67 | 30.12 | 28.75 |
4 trials available for bupivacaine and Spinal Diseases
14 other studies available for bupivacaine and Spinal Diseases
| Article | Year |
|---|---|
Retrospective Assessment of the Use of Liposomal Bupivacaine in Lumbar Fusions in Immediate Postoperative Hospital Care.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Bupivacaine; Female; Humans; Length of Stay; Lip | 2020 |
Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation.
Topics: Adult; Aged; Biomarkers; Bupivacaine; Cohort Studies; Epidural Space; Female; Follow-Up Studies; Hum | 2009 |
Adverse events of conscious sedation in ambulatory spine procedures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Anesthesia, Local; Bupiv | 2011 |
Intrathecal therapy-associated masses.
Topics: Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Catheterization; Diagnosis, Differential; Human | 2006 |
Anesthesia for Cesarean delivery in a parturient with rigid spine syndrome.
Topics: Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesth | 2006 |
Cutaneous reactions to injectable corticosteroids.
Topics: Aged; Anti-Inflammatory Agents; Bupivacaine; Diagnosis, Differential; Drug Eruptions; Female; Humans | 2006 |
Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain.
Topics: Aged; Australia; Bupivacaine; Diagnosis, Differential; Female; Humans; Injections, Intra-Articular; | 1995 |
The relative contributions of the disc and zygapophyseal joint in chronic low back pain.
Topics: Adult; Bupivacaine; Female; Humans; Intervertebral Disc; Intervertebral Disc Displacement; Lidocaine | 1994 |
Diagnostic value of intra-articular anaesthetic in primary osteoarthritis of the hip.
Topics: Anesthetics, Local; Arthroplasty, Replacement, Hip; Bupivacaine; Female; Follow-Up Studies; Hip Join | 1998 |
Cephalic spreading levels after volumetric caudal epidural injections in chronic low back pain.
Topics: Adult; Aged; Anesthesia, Epidural; Anesthetics, Local; Bupivacaine; Chronic Disease; Female; Fluoros | 2001 |
Extradural abscess following local anaesthetic and steroid injection for chronic low back pain.
Topics: Abscess; Aged; Anesthesia, Epidural; Anesthetics, Local; Back Pain; Bupivacaine; Chronic Disease; Di | 1990 |
Postmortem findings after epidural anaesthesia.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Anesthesia, Epidural; Bupivacaine; Epidural Spa | 1990 |
The diagnostic value of facet joint injections.
Topics: Adult; Aged; Bupivacaine; Contrast Media; Female; Humans; Injections, Spinal; Male; Middle Aged; Pai | 1988 |
Safety and efficacy of epidural analgesia in spine surgery.
Topics: Adult; Aged; Analgesia; Anesthesia, Epidural; Bupivacaine; Female; Humans; Intervertebral Disc Displ | 1986 |